VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
Kalyan Nadiminti(University of Iowa Hospitals and Clinics), Guido Tricot, Sarah L. Mott(University of Iowa), Allyson Schultz(University of Iowa Hospitals and Clinics), Kamal Kant Singh Abbi(University of Iowa Hospitals and Clinics), Sonya Behrends(University of Iowa Hospitals and Clinics), Fenghuang Zhan(Winthrop Rockefeller Foundation), Annick Tricot(University of Iowa Holden Comprehensive Cancer Center), Lindsay Dozeman(University of Iowa Hospitals and Clinics)
Cited by 5
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
|The Hematology Journal|2003|425
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
|Cancer Cell|2013|302
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274